Q-omics provides the consensus-scored PTTG3P profile across patient tissues and cancer cell-line models. PTTG3P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PTTG3P is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, PTTG3P RNA expression shows 10,775 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, COAD, and ACC as cancer lineages where PTTG3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTTG3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTTG3P survival associations across molecular data types. PTTG3P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTTG3P RNA expression–survival associations across cancer types. High PTTG3P expression shows unfavorable associations in UVM, LIHC, LUAD and ACC, but favorable associations in CESC and COAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PTTG3P RNA expression.
This table summarizes PTTG3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PTTG3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTTG3P shows higher tumor expression in COAD, STAD, HNSC, UCEC, BRCA and LUSC. The COAD box plot shows higher PTTG3P RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with PTTG3P in patient tissues and cancer cell lines. In patient samples, PTTG3P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTTG3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
